Skip to Content
Merck
CN

1.37206

SAFC

N1-Methyl-pseudouridine 5′-triphosphate

new

100 mM Sodium Solution, EMPROVE® EXPERT

Synonym(s):

1-N-Methyl-pseudo-UTP, N1-Me-pUTP, m1ΨTP

Sign Into View Organizational & Contract Pricing

Select a Size

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

synthetic

Quality Level

500

grade

GMP
Halal
Kosher

product line

EMPROVE® EXPERT

Assay

≥99%

form

solution

pH

7.0 ± 0.1

foreign activity

low in endotoxins

storage temp.

-10 to -25°C

SMILES string

O[C@H]1[C@@H](O[C@H](COP(OP(OP(=O)(O)O)(=O)O)(=O)O)[C@H]1O)C=2C(=O)NC(=O)N(C)C2

InChI

InChI=1S/C10H17N2O15P3/c1-12-2-4(9(15)11-10(12)16)8-7(14)6(13)5(25-8)3-24-29(20,21)27-30(22,23)26-28(17,18)19/h2,5-8,13-14H,3H2,1H3,(H,20,21)(H,22,23)(H,11,15,16)(H2,17,18,19)/t5-,6-,7-,8+/m1/s1

InChI key

OLRONOIBERDKRE-XUTVFYLZSA-N

General description

mRNA therapies represent a revolutionary approach to therapeutics such as vaccines, cancer treatments, and immunotherapies, offering novel ways to treat complex diseases. As a result, global interest in mRNA manufacturing has grown, while regulatory expectations have become increasingly exacting. In this environment, manufacturers require raw materials suitable for pharmaceutical use, ensuring the highest levels of quality and purity for successful mRNA production.

In response, we have developed the high-purity NTP Emprove® Expert portfolio, compliant with IPEC-PQG GMP standards, to ensure batch-to-batch consistency in your mRNA manufacturing processes. These critical raw materials are accompanied by comprehensive Emprove® dossiers, providing essential regulatory support to navigate the complexities of the biopharmaceutical industry while ensuring compliance and accelerating time to market.

Application

Nucleoside triphosphates (NTPs) are the key building blocks for messenger RNA (mRNA) constructs, which have valuable use as vaccines and therapeutics. The production of mRNA is carried out in an in vitro transcription (IVT) reaction, where enzymes use a plasmid DNA template to catalyze the linking of the NTP building blocks to create mRNA of the desired sequence. Our Emprove® Expert NTPs are designed to align with best practice IVT methods for mRNA manufacturing, possessing all the necessary chemical and biological properties for reliable production of therapeutic mRNA:

  • 100 mM sodium salt solution
  • Neutral pH (7.0 ± 0.1)
  • High chemical purity (≥99%)
  • Low endotoxin and bioburden
  • DNase and RNase-free
Designed especially with therapeutic mRNA manufacturing in mind, our range of Emprove® Expert NTPs boasts all of the quality attributes required for therapeutic mRNA raw materials, with validated quality control testing and manufacturing processes, certifications for AOF, Kosher, and Halal, and an extensive range of quality control parameters, provided in the COA.

Legal Information

Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Purchaser shall at all times be solely responsible for obtaining all necessary licenses and rights to use this product for its intended application and any compliance with existing laws and regulations. Purchaser understands that the seller is not liable for any patent infringement claims related to Purchaser’s use of this product

Regulatory Information

新产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service